Literature DB >> 27458560

Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Maurizio Salvadori1, Giuseppina Rosso1.   

Abstract

This review revises the reclassification of the membranoproliferative glomerulonephritis (MPGN) after the consensus conference that by 2015 reclassified all the glomerulonephritis basing on etiology and pathogenesis, instead of the histomorphological aspects. After reclassification, two types of MPGN are to date recognized: The immunocomplexes mediated MPGN and the complement mediated MPGN. The latter type is more extensively described in the review either because several of these entities are completely new or because the improved knowledge of the complement cascade allowed for new diagnostic and therapeutic approaches. Overall the complement mediated MPGN are related to acquired or genetic cause. The presence of circulating auto antibodies is the principal acquired cause. Genetic wide association studies and family studies allowed to recognize genetic mutations of different types as causes of the complement dysregulation. The complement cascade is a complex phenomenon and activating factors and regulating factors should be distinguished. Genetic mutations causing abnormalities either in activating or in regulating factors have been described. The diagnosis of the complement mediated MPGN requires a complete study of all these different complement factors. As a consequence, new therapeutic approaches are becoming available. Indeed, in addition to a nonspecific treatment and to the immunosuppression that has the aim to block the auto antibodies production, the specific inhibition of complement activation is relatively new and may act either blocking the C5 convertase or the C3 convertase. The drugs acting on C3 convertase are still in different phases of clinical development and might represent drugs for the future. Overall the authors consider that one of the principal problems in finding new types of drugs are both the rarity of the disease and the consequent poor interest in the marketing and the lack of large international cooperative studies.

Entities:  

Keywords:  C3 glomerulopathies; Complement dysregulation; Dense deposit disease; Glomerulonephritis reclassification; Membranoproliferative glomerulonephritis; Targeting complement pathways

Year:  2016        PMID: 27458560      PMCID: PMC4936338          DOI: 10.5527/wjn.v5.i4.308

Source DB:  PubMed          Journal:  World J Nephrol        ISSN: 2220-6124


  122 in total

Review 1.  The emerging role of complement inhibitors in transplantation.

Authors:  Véronique Frémeaux-Bacchi; Christophe M Legendre
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

2.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

Review 3.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

4.  Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies.

Authors:  L Skattum; U Mårtensson; A G Sjöholm
Journal:  J Intern Med       Date:  1997-12       Impact factor: 8.989

5.  C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

6.  Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H.

Authors:  T S Jokiranta; A Solomon; M K Pangburn; P F Zipfel; S Meri
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

7.  Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.

Authors:  Ozan Ozkaya; Hulya Nalcacioglu; Demet Tekcan; Gurkan Genc; Bilge Can Meydan; B Handan Ozdemir; M Kemal Baysal; Hasan Tahsin Keceligil
Journal:  Pediatr Nephrol       Date:  2014-01-26       Impact factor: 3.714

8.  Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.

Authors:  Cristina Rabasco; Teresa Cavero; Elena Román; Jorge Rojas-Rivera; Teresa Olea; Mario Espinosa; Virginia Cabello; Gema Fernández-Juarez; Fayna González; Ana Ávila; José María Baltar; Montserrat Díaz; Raquel Alegre; Sandra Elías; Monserrat Antón; Miguel Angel Frutos; Alfonso Pobes; Miguel Blasco; Francisco Martín; Carmen Bernis; Manuel Macías; Sergio Barroso; Alberto de Lorenzo; Gema Ariceta; Manuel López-Mendoza; Begoña Rivas; Katia López-Revuelta; José María Campistol; Santiago Mendizábal; Santiago Rodríguez de Córdoba; Manuel Praga
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

9.  C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.

Authors:  Agustín Tortajada; Hugo Yébenes; Cynthia Abarrategui-Garrido; Jaouad Anter; Jesús M García-Fernández; Rubén Martínez-Barricarte; María Alba-Domínguez; Talat H Malik; Rafael Bedoya; Rocío Cabrera Pérez; Margarita López Trascasa; Matthew C Pickering; Claire L Harris; Pilar Sánchez-Corral; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

Review 10.  Dense deposit disease and C3 glomerulopathy.

Authors:  Thomas D Barbour; Matthew C Pickering; H Terence Cook
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

View more
  5 in total

Review 1.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

Review 2.  Complement related kidney diseases: Recurrence after transplantation.

Authors:  Maurizio Salvadori; Elisabetta Bertoni
Journal:  World J Transplant       Date:  2016-12-24

3.  Immunotactoid Glomerulopathy with Nontuberculous Mycobacterial Infection: A Novel Association.

Authors:  Yoshio Shimizu; Keiichi Wakabayashi; Hiroyuki Iwasaki; Chiaki Kishida; Sayaka Seki; Teruyuki Okuma; Naoko Iwakami; Takumi Iwasawa; Hiroshi Maekawa; Yasuhiko Tomino; Ryo Wada; Yusuke Suzuki
Journal:  Case Rep Nephrol Dial       Date:  2021-06-17

4.  Characterization and Etiopathogenic Approach of Pediatric Renal Biopsy Patients in a Colombian Medical Center from 2007-2017.

Authors:  Mayerly Prada Rico; Carmen Inés Rodríguez Cuellar; Monica Fernandez Hernandez; Luz Stella González Chaparro; Olga Lucía Prado Agredo; Ricardo Gastelbondo Amaya
Journal:  Int J Nephrol       Date:  2018-06-28

Review 5.  PD-1 immunobiology in glomerulonephritis and renal cell carcinoma.

Authors:  Colleen S Curran; Jeffrey B Kopp
Journal:  BMC Nephrol       Date:  2021-03-06       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.